Inovio: What's the scoop?

Inovio stock is going bananas: traded 20M Friday and 32M yesterday. It is up 25% in two trading days and may be up again today. There is probably a goodly amount of daytrader activity as well. A good way of understanding what the company is about is to read the interview with CEO Dr Kim:

http://seekingalpha.com/article/2032351-the-real-inovio-pharmaceuticals-an-interview-with-dr-j-joseph-kim-ceo

Inovio is not the only company that is using the immune response as a way to fight cancer, but it has one ace in the hole: electroporation. This allows the introduction of purer antigens and a better immune response. We will soon be able to gauge the results of the first study. If the study shows a strong immune response (i.e. lots of antibodies against the papillary virus) then the vaccine can be said to be effective against the virus. But, if the treatment results in increased killer T cells, the sky is the limit. Those cells can remove cancer cells!

This is the issue: if Inovio's vaccine can prevent certain cancers, that is very valuable. But, if the treatment can stimulate killer T cell response and remove cancerous cells, that is another ball game.
Biotechs such as Inovio fail, because they either run out of money or their product is not approved by the FDA, because it does not work.

Here is another interview with Dr Kim. It explains the immunotherapies being contemplated or actually starting.

http://seekingalpha.com/article/1909711-inovio-ceo-interview-pd1-pdl1-inhibitors-immunotherapy-and-why-investors-should-be-excited-about-2014